热门资讯> 正文
Tempus AI扩大与Moderna、默克的癌症治疗协议
2026-10-07 21:01
- Tempus AI (TEM) announced on Wednesday that it expanded its multi-year deal with Moderna (MRNA) and Merck & Co. (MRK) to support the potential commercialization of intismeran autogene, an individualized cancer therapy.
- The company will manage tumor and blood sample collection and provide sequencing services, subject to regulatory approval, to support the therapy's development and manufacturing.
- The therapy is being evaluated with Keytruda in patients with stage IIB-IV melanoma and other cancers.
- Financial terms are yet to be disclosed.
- On the market side, Tempus AI traded about 3% lower at $70.07, while Moderna fell about 2% to $183.77. Moreover, Merck & Co. also traded slightly lower in premarket trading.
- Source: Press Release
More on Tempus AI
- Tempus AI: High Risk, But With A Great Cause
- Tempus AI: Data And Applications Will Unlock More Upside
- Tempus AI: Market Is Hyping On An Uncertain Number
- Personalis downgraded at BTIG on likely Tempus takeover
- Tempus AI gains as Cantor issues new Overweight on Data and applications segment
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。